# The Obesity-Drug Pipeline - Week of June 22, 2026: Retatrutide hits 28% weight loss; Lilly dethrones Keytruda

> GLP-1 and obesity-drug newsletter for the week of June 22, 2026. ADA 2026 broke decisively Lilly's way: retatrutide's TRIUMPH-1 posted near-surgical weight loss, the tirzepatide franchise displaced Keytruda as the world's top-selling drug, and contaminated placebo arms quietly became a regulatory problem for everyone chasing the leader.

## The Obesity-Drug Pipeline

### Week of June 22, 2026: Retatrutide hits 28% weight loss; Lilly dethrones Keytruda

---

ADA 2026 was the whole week, and it broke decisively one way. Lilly's triple-agonist retatrutide put up numbers that brush against bariatric surgery, the tirzepatide franchise knocked Keytruda off the top of the global drug-sales chart, and Novo's quarter went the other direction. Meanwhile the pipeline's dirty secret, patients keep wandering off placebo arms onto their own GLP-1s, quietly became a regulatory problem for everyone behind Lilly.

---

## TL;DR

- **Retatrutide is the new bar.** TRIUMPH-1 delivered **28.3% weight loss (70.3 lbs) over 80 weeks**, nearly half of patients past 30%, "encroaching on the outcomes we'd otherwise see with surgical options," per ADA's CSO ([JAMA Medical News](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOiclx9cmn6LSQW2jaaz5643FMhmbLRqK90gxQJDst6VYE2CWabGjvqetWlHAya5MlKcPA37FxczJGuemlP5vfDyiJornPmfePI3ZF55SMllJA-3D-3DNV5A_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbWnBdhzT7Wbpheblt-2F4gZ4Rlifz0yoLThfRrs7sbl7eblqbP-2B2Fo03AG-2FrtEjx8njESjwPyNmIEuCiO-2FLVtQ1fTKnvtR3b0eB86bw4w-2FqFDWI6Vbsxk8vpj6r-2FY-2BKw2rbpiJa4fDcHvTu3EmguKS-2BYBoWfZx8JqJBKbrDBkPNYfRQ-3D-3D)).
- **Lilly's franchise is the biggest drug on earth.** Q1 2026: Mounjaro **$8.66B** + Zepbound **$4.16B** = **$12.8B**; Mounjaro displaced Keytruda as #1 by quarterly sales. Novo's Ozempic and Wegovy both fell sequentially ([Citeline / Scrip](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgaK3KwKymSh-2FoTad1NRtqYMERPGaHNyiDhrAtu1cG53r8DtSXQSh5I6-2BA03aq9m8lDAGIVG44StrY57qo5SBBavhKoUWJvJS0BslZnQq8owQ-3D-3DryJc_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbWnBdhzT7Wbpheblt-2F4gZ4Rlifz0yoLThfRrs7sbl7ebqXnzzOqgkDDtR1I6bgmV4v4YEO87YRgjIzmlT24FGcEfot8KRtfr40weDUmo1vl5MoB8-2FKnH5tQQ2moIBs7UD-2BD-2Bxx5jod-2BggU9GJd-2Ba6YzxiVyFO3xXyxhY20Glm0tzQ-3D-3D)).
- **Payers are blinking.** CVS Caremark is **restoring Zepbound coverage**, reversing last summer's exclusion after an ERISA class-action and patient backlash ([CareTalk](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhPzhtNoB-2Bqlg7tjm7aUNQFEAgYPZ4bx9JkP2LsTvDMU9FByopomBdJIB8I2d4vLLTwHMmiP2T7tyLjNLHllS0gSdXsWS8yuAQXg3sFizK5mg-3D-3D55BP_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbWnBdhzT7Wbpheblt-2F4gZ4Rlifz0yoLThfRrs7sbl7ebrE4E-2BGI4pvHYzTSgQXiOeKTSzmHR2i5RqAqEF-2Bl6P2kBw29Cf-2BKtNcC2UDv47U7vkjqbfaNvGoFIVSYe0D9snRu8SW9zdW4KHm99yZHg6Oc7ONNerYfesFPSeFp0YZT-2BQ-3D-3D)).

---

## What's new

**Retatrutide redefines the efficacy ceiling.** On [JAMA Medical News](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOiclx9cmn6LSQW2jaaz5643FMhmbLRqK90gxQJDst6VYE2CWabGjvqetWlHAya5MlKcPA37FxczJGuemlP5vfDyiJornPmfePI3ZF55SMllJA-3D-3DiD3a_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbWnBdhzT7Wbpheblt-2F4gZ4Rlifz0yoLThfRrs7sbl7ebhoo5AXjJjbi2Q4NTxelm4my0O6dJW8ByQ9CG5KV6oLObg51T7c-2F-2BIOC3sFx8ecyxo7azIDNLfS7FR7I86sgYvgt9VtcnuedIKc0clPtkns7L-2FHhM5vORfFhemVMnCTLGg-3D-3D) ("Highlights From the ADA's 2026 Scientific Sessions"), Dr. Rita Kalyani, ADA Chief Scientific & Medical Officer, walked through two Lilly Phase 3 reads: TRANSCEND T2D-1 showed "up to a 2% reduction in A1c and a 16.8%... average loss of 36.6 pounds," and TRIUMPH-1 in obesity hit "28.3% over 80 weeks... on par with metabolic or bariatric surgery," with patients still losing out to 140 weeks. This resets the competitive ceiling for the entire next-gen field.

**The tirzepatide franchise becomes the world's biggest drug.** On [Citeline's "Scrip's Five Must-Know Things, June 22"](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgaK3KwKymSh-2FoTad1NRtqYMERPGaHNyiDhrAtu1cG53r8DtSXQSh5I6-2BA03aq9m8lDAGIVG44StrY57qo5SBBavhKoUWJvJS0BslZnQq8owQ-3D-3D6S36_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbWnBdhzT7Wbpheblt-2F4gZ4Rlifz0yoLThfRrs7sbl7ebicGmy9TjYusIhkjVRXgOtP95KdcIlii90P95wgawTl2qtFxyzYzY-2B9917HqXFbyB-2F1kVEYWTOgI1CyprU9ErwkqMaEGpt40CO5cHjMsa0-2FwMkrhvS5QIxR6uQfb9VMSzw-3D-3D), Mounjaro Q1 sales of **$8.66B** "more than doubling year-on-year," ex-US sales of **$4.4B overtaking US for the first time**, displacing Keytruda as #1. Full-year consensus: Mounjaro **$33.1B**, Zepbound **$19.3B**, four GLP-1 brands combining for **~$80B**. Ozempic is "forecast to drop from third place in 2025 to seventh."

**Novo's quarter went the wrong way.** Same episode: **Ozempic fell $602M and Wegovy fell $551M** versus Q4 2025, partly seasonal, partly "a modest shift towards the recently launched oral Wegovy formulation." Cannibalizing your own injectable is fine; losing share to Lilly while doing it is not.

**A payer reversal worth watching.** On [CareTalk: Healthcare. Unfiltered.](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhPzhtNoB-2Bqlg7tjm7aUNQFEAgYPZ4bx9JkP2LsTvDMU9FByopomBdJIB8I2d4vLLTwHMmiP2T7tyLjNLHllS0gSdXsWS8yuAQXg3sFizK5mg-3D-3DDQ-b_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbWnBdhzT7Wbpheblt-2F4gZ4Rlifz0yoLThfRrs7sbl7ebqCRFvWdl9bzSOh8fvx3xvYfvyg1nnh9CMkIUyq6q0PZY8fcqpqOfb7m6bpVVI6I3G16Y-2FEQZIWQBMRQypeWBEz3TzKp5AuDQ8NnEEIeL4yqxeq21jPzy3IWvSQ8kolblA-3D-3D) ("The Business & Science Behind the GLP-1 Boom"), host David Williams and John Driscoll, Chairman of UConn Health, flagged CVS Caremark "restoring coverage of Zepbound, reversing a formulary decision from last summer... which prompted patient anger and a class action lawsuit" alleging ERISA violations. The exclusion lever has legal costs: bullish for net volume, bearish for the "payers will crush price" thesis.

**The placebo problem is now a pipeline risk.** Across [On The Pen](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhkp9AGVkVfysq8OaJeqXYcitJEHJIf69XE3psxMhBlcIT5-2BWcoS6bLDZbdK9soK1YsjY1HjRdv0lm0NlVvPnF3EXX7D3BP5-2BZFziEoJREhJQ-3D-3D5403_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbWnBdhzT7Wbpheblt-2F4gZ4Rlifz0yoLThfRrs7sbl7ebpiGzhjjnvNCtS42DjLWb5BTUweRxTsEZ1nNdJIBK-2B3Er8fLqNajJbBtCR8lyJjJbWR-2B7ciyAe7QtUQ2lB3MmMZEJ0K18USXWDfWi89i3tS3csyGyG1LOu0aBl7CrWOkTA-3D-3D) and Scrip, the recurring ADA theme: placebo arms are contaminating as patients start their own GLP-1s. Boehringer/Zealand's cervidutide saw ~16% of placebo patients go on GLP-1s in Synchronized 1, dragging the arm to -5.4% and "casting doubt on whether Boehringer Ingelheim will submit." Roche's CT-388 had **34% of its placebo arm drop out**. Clean Phase 3 reads are getting structurally harder for everyone behind Lilly.

## The debate

**Bull:** The TAM keeps compounding. ADA showed efficacy still climbing toward surgical outcomes (retatrutide 28%), indications fanning out (CVD, MASH, sleep apnea, plus early signals in long COVID via NIH RECOVER and oncology at ASCO 2026, per [CareTalk](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhPzhtNoB-2Bqlg7tjm7aUNQFEAgYPZ4bx9JkP2LsTvDMU9FByopomBdJIB8I2d4vLLTwHMmiP2T7tyLjNLHllS0gSdXsWS8yuAQXg3sFizK5mg-3D-3Dpjop_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbWnBdhzT7Wbpheblt-2F4gZ4Rlifz0yoLThfRrs7sbl7ebszOSRqM-2B1XOtztpxzU1foWhoLBjuotNmXS89x7lwgzvOO3iGHiLbUFl0Z2y72pqSo4n7kFAwPIFcwGuMqSI0eJJMPJTesJsjGFXMkFDX96xkdRQCFZnkqNfATWgM8PkeQ-3D-3D)), and payers retreating from exclusions under legal pressure. On [Conversations on Health Care](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOg3CvfsCVEXQwnp-2BYdpjv-2BxWUceoJV-2FmWwn6txZMCeEtcFpkiEHoLe7KdmjzpBNBhaDQYVhtYgbwORz2ZmqD8f2Yhg-2Fu-2B1e4epsfQNmxQhkHQ-3D-3DUpQX_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbWnBdhzT7Wbpheblt-2F4gZ4Rlifz0yoLThfRrs7sbl7ebsqMUzxprCMXeOLAItfjOjZTuiFYOiqJ0HNdtnSOAC-2Fr-2BZ7ITfJWh-2B-2BcZj5WF-2FJECVq0WJ9JUB3UUXfZ1213caDAjLqAXcuX7JPcdNOD8bYD-2FPfMp1LR88y53zOfBpW-2Buw-3D-3D), Dr. Jamie Ard of Wake Forest called it "a watershed moment" with "roughly 110 million Americans eligible." Penetration is still single digits.

**Bear:** Demand isn't the question, durability and price are. Real-world persistence is ugly: CareTalk cited "50%... dropped them within six months" and "about 60% of weight loss... regained within a year after stopping," while BNY's guest put first-year discontinuation at "80% or more" ([Double Take, BNY Investments Newton](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOj0pyHZtyN5kFT6iKpx-2B4iNE2yZ1qBZ5ti8f6Mg-2By80NZpD10d-2BSoLZf9xK4gqXPVksnVuGd56UrTHUUEQVHyfFL5TVM59M4UpPReipTeBnig-3D-3DdRF1_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbWnBdhzT7Wbpheblt-2F4gZ4Rlifz0yoLThfRrs7sbl7ebuoy-2Fke9HsGaLzAkOBHzs-2BhK6lIVrvTCXqCj6gLvYGAoejOIf-2BjNtaeGGwSg1yLsQe6ixV7oGezzFaWWz-2F7HkaipGeW0ia0vyUPENHzeBrevR7DnALSp6B-2FK1P5PqnqIpw-3D-3D)). Add a crowded next-gen field, compounded GLP-1s that didn't die when the shortage ended (scripts still *rose* through Oct 2025), and Brazil-style patent/compulsory-licensing erosion, and net price per script compresses faster than Street models assume.

> **Our read:** This week widened the gap between the leader and everyone else. Lilly is pulling away on both efficacy and revenue; the bear case is increasingly a *second-tier* story about persistence and price for the followers, not the franchise.

---

## Stocks in play

| Ticker | Bull case | Bear case | Next catalyst |
| --- | --- | --- | --- |
| **LLY** | Retatrutide 28% weight loss; franchise now world's #1 drug | Persistence/regain caps real-world value; prices perfection | Retatrutide filing; more ADA/EASD reads ([JAMA](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOiclx9cmn6LSQW2jaaz5643FMhmbLRqK90gxQJDst6VYE2CWabGjvqetWlHAya5MlKcPA37FxczJGuemlP5vfDyiJornPmfePI3ZF55SMllJA-3D-3DkDYW_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbWnBdhzT7Wbpheblt-2F4gZ4Rlifz0yoLThfRrs7sbl7eblNsscyIhYd6cXhM-2FUKwBTf4GbJ0R7Ew4wrhve5L12hLc3UXZoGV05FvFGv0TQk-2B4ErUpBoDdKaQ11Qhv9K-2BPNXDqYl-2FZjb5cPD68P-2BGBQTcTDGRLK2kCpC8zPUM9SD56Q-3D-3D)) |
| **NVO** | Oral Wegovy launch; CagriSema Re-imagined hit 13.6% weight loss | Ozempic -$602M, Wegovy -$551M QoQ; CagriSema tolerability (60–69% completed top dose) | CagriSema path; oral Wegovy ramp ([On The Pen](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhkp9AGVkVfysq8OaJeqXYcitJEHJIf69XE3psxMhBlcIT5-2BWcoS6bLDZbdK9soK1YsjY1HjRdv0lm0NlVvPnF3EXX7D3BP5-2BZFziEoJREhJQ-3D-3DVll4_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbWnBdhzT7Wbpheblt-2F4gZ4Rlifz0yoLThfRrs7sbl7ebj9r8sH2wwUcmNSIgsw5R2-2FbtociOSqbjUPesO2msB0MXNVA41mIWhmDPhSggGOkPk4D-2BBNbiiS4xJibPBX4RbINNsa1ViFzCx01vGSB8m3ZSLZFt9kwUQjeuIIiCUtUSw-3D-3D)) |
| **Roche (RHHBY)** | CT-388 dual agonist still in the mix | 34% placebo-arm dropout muddies the read | Cleaner CT-388 data ([Scrip](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgaK3KwKymSh-2FoTad1NRtqYMERPGaHNyiDhrAtu1cG53r8DtSXQSh5I6-2BA03aq9m8lDAGIVG44StrY57qo5SBBavhKoUWJvJS0BslZnQq8owQ-3D-3DtzQv_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbWnBdhzT7Wbpheblt-2F4gZ4Rlifz0yoLThfRrs7sbl7ebr5KJjSFBB9L7xVEIWrFXB-2FHf7sjtinDXrN7IsvxfidsAdefptF3oimbh-2BzuEqKYjrIFasEdvbjfhaG0L-2FWBo6X6VVNbbvwqekkFyLfdVulJVVK4IkQozCsAa6e8G9YOzA-3D-3D)) |
| **CVS** | Caremark Zepbound reinstatement = more covered scripts | ERISA litigation cut both ways | 2027 formulary design ([CareTalk](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhPzhtNoB-2Bqlg7tjm7aUNQFEAgYPZ4bx9JkP2LsTvDMU9FByopomBdJIB8I2d4vLLTwHMmiP2T7tyLjNLHllS0gSdXsWS8yuAQXg3sFizK5mg-3D-3DP2dZ_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbWnBdhzT7Wbpheblt-2F4gZ4Rlifz0yoLThfRrs7sbl7ebpYiFQYyBGYC5YVow2-2ByDdqJOHfMU7qbVNRUe3jtWJDltRS8NclOnx1u7SM3wlhAZEUe8ie5f-2FBcDXtpQfvCJ-2BlVuTAqL7AXsgygU7-2B52D9sE0HlhaqfOdakt15EJa3k-2Fw-3D-3D)) |
| **PFE** | Oral GLP-1 "faster weight loss than weekly Ozempic" | Far behind on data and scale | Oral GLP-1 late-stage reads ([Conversations](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOg3CvfsCVEXQwnp-2BYdpjv-2BxWUceoJV-2FmWwn6txZMCeEtcFpkiEHoLe7KdmjzpBNBhaDQYVhtYgbwORz2ZmqD8f2Yhg-2Fu-2B1e4epsfQNmxQhkHQ-3D-3DBosJ_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbWnBdhzT7Wbpheblt-2F4gZ4Rlifz0yoLThfRrs7sbl7ebuYKyvQ0VUmn7CTcGNMK4hOpx9IX7uP4kFeK-2F-2B-2FgpAzT8Q8EXdFDRPkwKaWgeTcdgEfilVPLM2peOBbT6QlqGrhNxYtLJ33-2FklWz7GqqVg-2FddLqJ-2FUtTF8-2BHYeXMnYD9KQ-3D-3D)) |

## Read-throughs

- **Fast-followers (AMGN, VKTX, Roche):** Amgen MariTide and Viking VK2735 drew zero coverage this week, notable for an ADA week. Roche's CT-388 surfaced only as the placebo-dropout cautionary tale. The retatrutide bar raises the "good enough to compete" threshold for all three.
- **Contract manufacturing / fill-finish (CTLT, LNZA, TMO):** Silent, no capacity or buildout chatter despite the volume ramp. Silence is data.
- **Pen / auto-injector suppliers (Ypsomed, Gerresheimer, Phillips Medisize):** Silent. The oral-formulation shift (oral Wegovy, orforglipron, Pfizer's pill) is the structural overhang to watch, but nothing new this week.
- **Insurers / PBMs (CVS, CI, UNH):** Only CVS active, via the Caremark reversal. Cigna/Express Scripts and UNH/Optum Rx quiet.
- **Medtech / bariatric:** No direct names, but retatrutide framed as "on par with... bariatric surgery," a structural negative read-through for procedure volumes.
- **Food / QSR:** Silent.

## What changed vs. last week

Issue #1 of the series, no prior issue to diff against. Baseline set: Lilly leads on efficacy and revenue; Novo declining sequentially; CVS reversing on coverage; placebo contamination emerging as a cross-pipeline risk. Quiet this week and worth watching for movement: Novo CMD/CEO commentary, MariTide and VK2735, contract-manufacturing and pen-supplier capacity, and state-level Rx legislation.